This profile is built from public research funding records (CIHR, NSERC and SSHRC). We have not imported them from a McGill University directory, so their publications, courses and email address may be missing. Find their university profile.
Research
Latest funding
- $1,154,425
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Principal investigator
- $4,617,694
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
CIHR · 2023 · Principal investigator
- $150,000
Evaluation of digital chest x-ray analysis with commercial artificial intelligence-based software for tuberculosis diagnosis in Ca Mau, Vietnam
CIHR · 2021 · Supervisor
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
Principal investigators: Menzies, Richard; Campbell, Jonathon; Fox, Gregory; Golchi, Shirin; Johnston, James C; Law, Stephanie; Long, Richard; Lupien, Andréanne; Ruslami, Rovina
Keywords: Acceptability; Adaptive Trial; Cost-Effectiveness; Multi-Arm Trial; Multicentre Trial; Randomized Trial; Safety; Tolerability; Tuberculosis; Tuberculosis Prevention
Finding the right balance: An adaptive trial to identify the safest regimen with the shortest duration for TB prevention (treatment of TB Infection)
Principal investigators: Menzies, Richard; Campbell, Jonathon; Fox, Gregory; Golchi, Shirin; Johnston, James C; Law, Stephanie; Long, Richard; Lupien, Andréanne; Ruslami, Rovina
Keywords: Acceptability; Adaptive Trial; Cost-Effectiveness; Multi-Arm Trial; Multicentre Trial; Randomized Trial; Safety; Tolerability; Tuberculosis; Tuberculosis Prevention
Evaluation of digital chest x-ray analysis with commercial artificial intelligence-based software for tuberculosis diagnosis in Ca Mau, Vietnam
Principal investigators: MacLean, Emily L
Keywords: Clinical Trial; Computer-Aided Detection; Diagnostic Testing; Epidemiology; Global Health; Tuberculosis
Tackling the two greatest obstacles to Tuberculosis elimination: Treatment of latent infection and drug resistant disease.
Principal investigators: Menzies, Richard
Keywords: Cost Effectiveness Analysis; Drug Resistance; Infectious Disease Modeling; Latent Tuberculosis; Randomized Trial; Systematic Reviews And Meta-Analyses; Tuberculosis; Tuberculosis Prevention; Tuberculosis Treatment
From CIHR, NSERC and SSHRC funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998, including their latest published competition results.
A short, specific email works best. This draft uses one of their recent papers; replace the parts in brackets with your own details before sending.